Evidence map›Paper›PMID 30919155›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2019

Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.

Vasiliki Nikolaou, D Voudouri, G Tsironis, A Charpidou, G Stamoulis, I Triantafyllopoulou, I Panoutsopoulou, E Xidakis, A Bamias, E Samantas and 5 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Characterization of the role of Facebook groups for patients who use scalp cooling therapy: a survey study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  5. Review
  6. Article
  7. Supportive oncodermatology-a narrative review of its utility and the way forward.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Vasiliki NikolaouDermato-Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece. drviknik@yahoo.com.
D VoudouriDermato-Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
G TsironisDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
A CharpidouThird Department of Medicine, Oncology Unit, Sotiria General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
G StamoulisThird Department of Medical Oncology, Agii Anargiri General Oncological Hospital of Kifissia, Athens, Greece.
I TriantafyllopoulouDermato-Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
I PanoutsopoulouDermato-Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
E XidakisSecond Department of Medical Oncology, Agii Anargiri General Oncological Hospital of Kifissia, Athens, Greece.
A BamiasDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
E SamantasThird Department of Medical Oncology, Agii Anargiri General Oncological Hospital of Kifissia, Athens, Greece.
G AravantinosSecond Department of Medical Oncology, Agii Anargiri General Oncological Hospital of Kifissia, Athens, Greece.
H GogasOncology Section, First Department of Internal Medicine, General Hospital of Athens "Laiko", National and Kapodistrian University of Athens, Athens, Greece.
D RigopoulosDermato-Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
K SyrigosThird Department of Medicine, Oncology Unit, Sotiria General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
A StratigosDermato-Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCutaneous toxicities from novel anticancer treatments are an emerging problem in dermato-oncology. However, the prevalence of those toxicities and necessity of skin consultations are currently unknown. The purpose of our study was to perform an epidemiologic analysis of cutaneous toxicities that were referred to our cutaneous toxicity clinic in Athens, Greece.

methodsAll patients examined at the oncodermatology department over a 42-month period were included. Gender, age, type of cancer, type of antineoplastic treatment, and type of toxicity were recorded and analyzed.

resultsFour hundred fifty-nine patients (182 males, 277 females) with mean age (SD) 60.6 years (13.05) were included in the analysis. Six hundred seventy-two cutaneous toxicities were recorded. Chemotherapy-induced toxicities were the most commonly recorded incidents, with taxanes being the most commonly involved agent. Immune-related adverse events (IRAEs) have steadily increased over the past 3 years. Treatment modifications due to skin toxicities were more common in patients treated with targeted agents and immune checkpoint inhibitors than in those treated with chemotherapy. The toxicities that led to the most treatment modifications were acneiform eruptions and perionychias. The most common IRAEs recorded were psoriasis in 11 patients, followed by pruritus, macular rash, and lichenoid-type eruptions. In addition, 4 interesting cases of IRAEs are discussed.

conclusionAntineoplastic treatments can lead to a wide range of cutaneous toxicities. Our study underlines the need for a multidisciplinary approach in oncologic patients. The dermatologists' role is crucial in effectively managing those reactions and preventing antineoplastic drug dose adjustments or discontinuation of treatment.

Indexed as

Acneiform EruptionsAgedAntineoplastic AgentsDrug EruptionsExanthemaFemaleGreeceHumansMaleMiddle AgedNeoplasmsRetrospective StudiesSkinAntineoplastic AgentsAcneiform eruptionCutaneous toxicitiesImmune-related adverse effectsPerionychia

Identifiers

PMID30919155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.